MA29432B1 - Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques - Google Patents
Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiquesInfo
- Publication number
- MA29432B1 MA29432B1 MA30221A MA30221A MA29432B1 MA 29432 B1 MA29432 B1 MA 29432B1 MA 30221 A MA30221 A MA 30221A MA 30221 A MA30221 A MA 30221A MA 29432 B1 MA29432 B1 MA 29432B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- glucagon receptor
- preparation
- methods
- receptor antagonists
- Prior art date
Links
- 229940122904 Glucagon receptor antagonist Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940125425 inverse agonist Drugs 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002469 receptor inverse agonist Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES NOUVEAUX COMPOSÉS DE FORMULE (I) OU DES SELS ASSOCIÉS ACCEPTABLES PHARMACEUTIQUEMENT QUI POSSÈDENT UN ANTAGONISTE DU RÉCEPTEUR DU GLUCAGON OU UNE ACTIVITÉ AGONISTE INVERSE, AINSI QUE DES MÉTHODES D'UTILISATION DE CES COMPOSÉS ET INTERMÉDIAIRES ET DES MÉTHODES DE PRÉPARATION DE TELS COMPOSÉS. DANS UN AUTRE MODE DE RÉALISATION, CETTE INVENTION A POUR OBJET DES COMPOSITIONS PHARMACEUTIQUES RENFERMANT DES COMPOSÉS DE FORMULE (I), AINSI QUE DES MÉTHODES LES EMPLOYANT DANS LE TRAITEMENT DE TROUBLES DIABÉTIQUES ET D'AUTRES TROUBLES MÉTABOLIQUES LIÉS AU GLUCAGON, ET SIMILAIRE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65249205P | 2005-02-11 | 2005-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29432B1 true MA29432B1 (fr) | 2008-05-02 |
Family
ID=36694345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30221A MA29432B1 (fr) | 2005-02-11 | 2007-09-11 | Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8084489B2 (fr) |
| EP (1) | EP1856090B1 (fr) |
| JP (1) | JP4988604B2 (fr) |
| KR (1) | KR20070104409A (fr) |
| CN (1) | CN101115735B (fr) |
| AT (1) | ATE445609T1 (fr) |
| AU (1) | AU2006213894B2 (fr) |
| BR (1) | BRPI0607015A2 (fr) |
| CA (1) | CA2597073C (fr) |
| CR (1) | CR9304A (fr) |
| CY (1) | CY1109624T1 (fr) |
| DE (1) | DE602006009773D1 (fr) |
| DK (1) | DK1856090T3 (fr) |
| EA (1) | EA200701705A1 (fr) |
| ES (1) | ES2332470T3 (fr) |
| IL (1) | IL184932A0 (fr) |
| MA (1) | MA29432B1 (fr) |
| MX (1) | MX2007009661A (fr) |
| NO (1) | NO20074567L (fr) |
| PL (1) | PL1856090T3 (fr) |
| PT (1) | PT1856090E (fr) |
| SI (1) | SI1856090T1 (fr) |
| TN (1) | TNSN07313A1 (fr) |
| WO (1) | WO2006086488A2 (fr) |
| ZA (1) | ZA200706354B (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1968921B (zh) * | 2004-06-14 | 2011-11-23 | 伊莱利利公司 | 胰高血糖素受体拮抗剂、制备和治疗用途 |
| KR20200123866A (ko) | 2007-02-09 | 2020-10-30 | 메타베이시스 테라퓨틱스, 인크. | 글루카곤 수용체의 길항제 |
| EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
| PT2799428T (pt) | 2008-08-13 | 2017-02-17 | Metabasis Therapeutics Inc | Antagonistas de glicagina |
| WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
| EP2582709B1 (fr) | 2010-06-18 | 2018-01-24 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| NZ611529A (en) | 2010-12-23 | 2015-06-26 | Pfizer | Glucagon receptor modulators |
| WO2012107850A1 (fr) | 2011-02-08 | 2012-08-16 | Pfizer Inc. | Modulateur du récepteur de glucagon |
| EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (fr) | 2011-03-08 | 2014-12-17 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
| EP2766349B1 (fr) | 2011-03-08 | 2016-06-01 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
| WO2012120056A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| US8927577B2 (en) | 2011-07-22 | 2015-01-06 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
| WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
| WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
| TW201427658A (zh) | 2012-12-10 | 2014-07-16 | Merck Sharp & Dohme | 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法 |
| EP3065736B1 (fr) | 2013-11-04 | 2018-11-14 | Merck Sharp & Dohme Corp. | Composés antagonistes du récepteur du glucagon, compositions correspodantes et méthodes d'utilisation |
| WO2015191900A1 (fr) | 2014-06-12 | 2015-12-17 | Ligand Pharmaceuticals, Inc. | Antagonistes du glucagon |
| EP3350200A4 (fr) | 2015-09-18 | 2019-03-27 | Wake Forest University Health Services | Analogues d'angiotensine (1-7) et procédés associés |
| US20180289859A1 (en) | 2015-10-05 | 2018-10-11 | Hettwer Holding Aps | Compositions and methods for treatment of bone defects |
| CA2914601A1 (fr) * | 2015-12-11 | 2017-06-11 | Wake Forest University Health Sciences | Analogues d'angiotensine-(1-7) et methodes associees |
| NZ750953A (en) | 2016-08-30 | 2026-02-27 | Regeneron Pharma | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| CA3071387A1 (fr) | 2017-08-22 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Methodes de traitement des troubles lies au cycle de l'uree par interference avec la signalisation du recepteur du glucagon |
| WO2019160940A1 (fr) | 2018-02-13 | 2019-08-22 | Ligand Pharmaceuticals Incorporated | Antagonistes de récepteur de glucagon |
| CN118496197A (zh) | 2019-12-20 | 2024-08-16 | 拜耳公司 | 取代的噻吩甲酰胺、噻吩甲酸及其衍生物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005511683A (ja) | 2001-12-03 | 2005-04-28 | ノボ ノルディスク アクティーゼルスカブ | 新規なグルカゴンアンタゴニスト |
| EP1519723A1 (fr) | 2002-06-27 | 2005-04-06 | Novo Nordisk A/S | Nouveaux antagonistes/agonistes inverses du glucagon |
| US7989457B2 (en) * | 2004-05-28 | 2011-08-02 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| CN1968921B (zh) * | 2004-06-14 | 2011-11-23 | 伊莱利利公司 | 胰高血糖素受体拮抗剂、制备和治疗用途 |
-
2006
- 2006-02-09 ES ES06720513T patent/ES2332470T3/es not_active Expired - Lifetime
- 2006-02-09 DK DK06720513T patent/DK1856090T3/da active
- 2006-02-09 KR KR1020077018437A patent/KR20070104409A/ko not_active Ceased
- 2006-02-09 BR BRPI0607015-9A patent/BRPI0607015A2/pt not_active IP Right Cessation
- 2006-02-09 PT PT06720513T patent/PT1856090E/pt unknown
- 2006-02-09 EA EA200701705A patent/EA200701705A1/ru unknown
- 2006-02-09 DE DE602006009773T patent/DE602006009773D1/de not_active Expired - Lifetime
- 2006-02-09 AU AU2006213894A patent/AU2006213894B2/en not_active Ceased
- 2006-02-09 PL PL06720513T patent/PL1856090T3/pl unknown
- 2006-02-09 AT AT06720513T patent/ATE445609T1/de active
- 2006-02-09 US US11/815,987 patent/US8084489B2/en not_active Expired - Fee Related
- 2006-02-09 CA CA2597073A patent/CA2597073C/fr not_active Expired - Fee Related
- 2006-02-09 JP JP2007555195A patent/JP4988604B2/ja not_active Expired - Fee Related
- 2006-02-09 EP EP06720513A patent/EP1856090B1/fr not_active Expired - Lifetime
- 2006-02-09 MX MX2007009661A patent/MX2007009661A/es active IP Right Grant
- 2006-02-09 WO PCT/US2006/004461 patent/WO2006086488A2/fr not_active Ceased
- 2006-02-09 CN CN2006800046189A patent/CN101115735B/zh not_active Expired - Fee Related
- 2006-02-09 SI SI200630534T patent/SI1856090T1/sl unknown
-
2007
- 2007-07-30 IL IL184932A patent/IL184932A0/en unknown
- 2007-07-31 ZA ZA200706354A patent/ZA200706354B/xx unknown
- 2007-08-10 TN TNP2007000313A patent/TNSN07313A1/en unknown
- 2007-08-10 CR CR9304A patent/CR9304A/es not_active Application Discontinuation
- 2007-09-10 NO NO20074567A patent/NO20074567L/no not_active Application Discontinuation
- 2007-09-11 MA MA30221A patent/MA29432B1/fr unknown
-
2009
- 2009-11-12 CY CY20091101192T patent/CY1109624T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1856090T3 (da) | 2009-11-30 |
| JP4988604B2 (ja) | 2012-08-01 |
| WO2006086488A2 (fr) | 2006-08-17 |
| AU2006213894B2 (en) | 2011-12-08 |
| US8084489B2 (en) | 2011-12-27 |
| ATE445609T1 (de) | 2009-10-15 |
| CA2597073A1 (fr) | 2006-08-17 |
| SI1856090T1 (sl) | 2010-02-26 |
| US20100137417A1 (en) | 2010-06-03 |
| TNSN07313A1 (en) | 2008-12-31 |
| ZA200706354B (en) | 2008-11-26 |
| EA200701705A1 (ru) | 2008-02-28 |
| EP1856090B1 (fr) | 2009-10-14 |
| EP1856090A2 (fr) | 2007-11-21 |
| CN101115735A (zh) | 2008-01-30 |
| DE602006009773D1 (de) | 2009-11-26 |
| PL1856090T3 (pl) | 2010-02-26 |
| AU2006213894A1 (en) | 2006-08-17 |
| JP2008530102A (ja) | 2008-08-07 |
| CR9304A (es) | 2008-03-31 |
| PT1856090E (pt) | 2009-11-18 |
| CN101115735B (zh) | 2013-01-09 |
| MX2007009661A (es) | 2007-09-25 |
| ES2332470T3 (es) | 2010-02-05 |
| CY1109624T1 (el) | 2014-08-13 |
| IL184932A0 (en) | 2007-12-03 |
| CA2597073C (fr) | 2014-11-25 |
| BRPI0607015A2 (pt) | 2009-12-01 |
| KR20070104409A (ko) | 2007-10-25 |
| WO2006086488A3 (fr) | 2006-12-14 |
| NO20074567L (no) | 2007-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29432B1 (fr) | Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques | |
| NO20070213L (no) | Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| WO2007106181A3 (fr) | Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques | |
| DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
| WO2007120270A3 (fr) | Antagonistes de récepteur du glucagon, procédés de préparation et utilisations thérapeutiques | |
| DK1951659T3 (da) | Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf | |
| CY1109694T1 (el) | Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης |